Modality
Small Molecule
MOA
SOS1i
Target
TIM-3
Pathway
JAK/STAT
OCD
Development Pipeline
Preclinical
~Jun 2019
→ ~Sep 2020
Phase 1
Dec 2020
→ Feb 2026
Phase 1Current
NCT04300741
178 pts·OCD
2020-12→2026-02·Recruiting
NCT04691001
2,317 pts·OCD
2024-11→2026-02·Recruiting
2,495 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-02-082mo agoPh2 Data· OCD
2026-02-092mo agoPh2 Data· OCD
Trial Timeline
2021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026
P1/2
Recruit…
P1/2
Recruit…
Catalysts
Ph2 Data
2026-02-08 · 2mo ago
OCD
Ph2 Data
2026-02-09 · 2mo ago
OCD
Recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04300741 | Phase 1/2 | OCD | Recruiting | 178 | Safety |
| NCT04691001 | Phase 1/2 | OCD | Recruiting | 2317 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| REG-647 | Regeneron | Preclinical | SMN2 | |
| REG-6699 | Regeneron | Phase 2/3 | TIM-3 | |
| Cevisacituzumab | Alnylam | Preclinical | MALT1 | |
| Nidasacituzumab | United Therapeutics | Phase 1/2 | TIM-3 |